Holen Sie sich die Stockscreener-App
2.28
1.72%
-0.04
Handel nachbörslich:
2.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.32
Offen:
$2.28
24-Stunden-Volumen:
906.68K
Relative Volume:
0.87
Marktkapitalisierung:
$110.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-1.6522
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
-2.56%
1M Leistung:
+7.04%
6M Leistung:
-4.20%
1J Leistung:
-90.46%
1-Tages-Spanne:
$2.26
$2.35
1-Wochen-Bereich:
$2.14
$2.42
52-Wochen-Spanne:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Vergleichen Sie SAVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.28 | 112.07M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Why is Cassava Sciences Inc. Equity Warrant stock going downTop Earnings Growth Momentum Picks - thegnnews.com
Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionTrend Following High Return Picks - thegnnews.com
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewswire
Cassava Sciences Boosts Medical Leadership with New CMO Appointment, Analysts Maintain Cautionary Price Target - AInvest
Cassava Sciences appoints Hulihan as Chief Medical Officer - TipRanks
Cassava Sciences appoints Dr. Joseph Hulihan as Chief Medical Officer - MarketScreener
Cassava Sciences' Strategic Hire of Joe Hulihan as CMO: A Catalyst for Accelerated Pipeline Development in Neurodegenerative Therapeutics - AInvest
Cassava Sciences appoints Joseph Hulihan as chief medical officer By Investing.com - Investing.com South Africa
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Simufilam reduces tuberous sclerosis-associated seizures - BioWorld MedTech
Cassava Sciences Announces Positive Preclinical Results - TipRanks
SAVA’s simufilam cuts seizures in TSC mice; first human trial slated H1 2026 | SAVA SEC FilingForm 8-K - Stock Titan
Cassava Sciences Reports Positive Preclinical Results for Simufilam in Tuberous Sclerosis Complex-Related Epilepsy - Quiver Quantitative
Cassava Sciences and Simufilam: A Groundbreaking Opportunity in TSC-Related Epilepsy - AInvest
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - The Manila Times
What analysts say about Cassava Sciences Inc. Equity Warrant stockInvest like a pro with expert recommendations - Jammu Links News
What is the risk reward ratio of investing in Cassava Sciences Inc. stockTremendous growth opportunities - Jammu Links News
Why is Cassava Sciences Inc. stock attracting strong analyst attentionUncover the best stocks for explosive growth - Jammu Links News
Is Cassava Sciences Inc. stock overvalued or undervaluedMaximize your returns with portfolio optimization - Jammu Links News
What catalysts could drive Cassava Sciences Inc. stock higher in 2025Consistently high returns - Jammu Links News
Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastTremendous gains - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. stockPhenomenal capital gains - Jammu Links News
What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantFree Trading Strategy Suggestions - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. Equity Warrant stockSuperior stock selection - Jammu Links News
Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedMaximize your portfolio’s growth potential - Jammu Links News
What is the dividend policy of Cassava Sciences Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyExponential wealth increase - Jammu Links News
How does Cassava Sciences Inc. compare to its industry peersHigh-profit stock alerts - Jammu Links News
How does Cassava Sciences Inc. generate profit in a changing economyExponentially increasing returns - Jammu Links News
Should I hold or sell Cassava Sciences Inc. Equity Warrant stock in 2025Maximize returns with smart investment plans - Jammu Links News
What drives Cassava Sciences Inc. Equity Warrant stock priceMarket-leading capital gains - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. in the next 12 monthsExceptional profit margins - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. Equity Warrant in the next 12 monthsCapitalize on emerging market opportunities - Jammu Links News
What is Cassava Sciences Inc. Equity Warrant company’s growth strategyMaximize returns with effective portfolio management - Jammu Links News
Why is Cassava Sciences Inc. Equity Warrant stock attracting strong analyst attentionExceptional trading performance - Jammu Links News
What catalysts could drive Cassava Sciences Inc. Equity Warrant stock higher in 2025Unstoppable profit momentum - Jammu Links News
When is Cassava Sciences Inc. Equity Warrant stock expected to show significant growthTremendous return rates - Jammu Links News
How strong is Cassava Sciences Inc. company’s balance sheetInvest smarter with high-probability setups - Jammu Links News
What institutional investors are buying Cassava Sciences Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What analysts say about Cassava Sciences Inc. stockHigh-profit capital plays - Jammu Links News
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today! - ACCESS Newswire
What is Cassava Sciences Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Should I hold or sell Cassava Sciences Inc. stock in 2025Smart Portfolio Strategy With High Returns - Jammu Links News
Using Bollinger Bands to evaluate Cassava Sciences Inc. Equity WarrantExpert Verified Stock Trade Ideas Backed by Data - metal.it
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):